I find it very interesting that valuations have seemed to now be underestimating NEU, whereas before our fantastic phase-3 results, we were being pumped by analytical publications.
I remember before the success of P3, we were valued at over $3 multiple times and that we were worth that amount in that moment. Posters on here were also extremely optimistic about our value.
Now that we have results that really has left no ifs or buts about whether Trofinitide works or not, valuations seem to be extremely cautious. Between $5 to $7? Despite NEU set to receive payments and royalties, still has to partner for ROW...not even to mention the other medications coming through. It does not make cents. When it doesn't make cents it makes dollars.
Instead of pressing on hard and being stubborn to get our true value, I have a feeling we are being oiled up to accept a low T/O.
NEU Price at posting:
$3.63 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)